Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coco, M.
Right arrow Articles by Malluche, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coco, M.
Right arrow Articles by Malluche, H.
J Am Soc Nephrol 14:2669-2676, 2003
© 2003 American Society of Nephrology

CLINICAL SCIENCE

Prevention of Bone Loss in Renal Transplant Recipients: A Prospective, Randomized Trial of Intravenous Pamidronate

Maria Coco*, Daniel Glicklich*, Marie Claude Faugere{dagger}, Larry Burris*, Istvan Bognar*, Peter Durkin*, Vivian Tellis*, Stuart Greenstein*, Richard Schechner*, Katherine Figueroa*, Patricia McDonough*, Guodong Wang{dagger} and Hartmut Malluche{dagger}

*Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York; and {dagger}University of Kentucky, Lexington, Kentucky

Correspondence to Dr. Maria Coco, Montefiore Medical Center, 111 East 210th Street, Bronx, New York 10467. Phone: 718-920-4136; Fax: 718-652-8384;


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
ABSTRACT. Renal transplant recipients are at risk of developing bone abnormalities that result in bone loss and bone fractures. These are related to underlying renal osteodystrophy, hypophosphatemia, and immunosuppressive treatment regimen. Although bisphosphonates are useful in ameliorating bone mineral loss after transplantation, it is not known whether their use in renal transplant patients leads to excessive suppression of bone turnover and increased incidence of adynamic bone disease. A randomized, prospective, controlled, clinical trial was conducted using the bisphosphonate pamidronate intravenously in patients with new renal transplants. Treatment subjects (PAM) received pamidronate with vitamin D and calcium at baseline and at months 1, 2, 3, and 6. Control (CON) subjects received vitamin D and calcium only. During months 6 to 12, the subjects were observed without pamidronate treatment. Biochemical parameters of bone turnover were obtained monthly and, bone mineral density (BMD) was obtained at baseline and months 6 and 12. Bone biopsies for mineralized bone histology were obtained at baseline and at 6 mo in a subgroup of subjects who underwent scheduled living donor transplantation. PAM preserved bone mass at 6 and 12 mo as measured by bone densitometry and histomorphometry. CON had decreased vertebral BMD at 6 and 12 mo (4.8 ± 0.08 and 6.1 ± 0.09%, respectively). Biochemical parameters of bone turnover were similar in both groups at 6 and 12 mo. Bone histology revealed low turnover bone disease in 50% of the patients at baseline. At 6 mo, all of PAM had adynamic bone disease, whereas 50% of CON continued to have or developed decreased bone turnover. Pamidronate preserved vertebral BMD during treatment and 6 mo after cessation of treatment. Pamidronate treatment was associated with development of adynamic bone histology. Whether an improved BMD with adynamic bone histology is useful in maintaining long-term bone health in renal transplant recipients requires further study. E-mail: mcoco@montefiore.org


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Patients with ESRD are known to have a spectrum of bone disease, ranging from high-turnover bone disease (hyperparathyroid bone disease with or without mineralization defect) to low-turnover bone disease (adynamic bone disease, osteomalacia) (1,2). Osteopenia may also be present and may worsen secondary to immunosuppression (3) or other factors (4). Therefore, the bone disease that develops after renal transplantation differs from the posttransplantation osteoporosis seen after other solid-organ transplantations.

Corticosteroids induce bone loss through depressive effects on osteoblastic activity and enhancing effects on osteoclastic activity (5,6), lowering of gastrointestinal calcium absorption, increased renal calcium excretion, and increased parathyroid hormone (PTH) secretion, all resulting in decreased bone mass (5). Cyclosporine and tacrolimus can affect bone remodeling which can result in increased bone loss (7,8). As a result, 6.8 and 8.8% of bone mineral density (BMD) can be lost by 6 and 18 mo, respectively, after successful renal transplantation (9). Consequently, there is an increased risk for fractures in this population (10).

Bone loss in patients with osteoporosis or those who receive corticosteroid therapy has been treated effectively with bisphosphonates (3,11,12). Bisphosphonates decrease bone turnover mainly by inhibiting osteoclast activity. They have been used with varying success in treatment of bone loss associated with cardiac (13,14) and liver transplantation (15–17). Recent studies have shown favorable effects on BMD in renal transplant recipients (18,19).

It has been shown that renal transplant recipients develop low bone turnover with time (20). A cross-sectional study in renal transplant patients demonstrated a high prevalence of low-turnover or adynamic bone disease with and without mineralization defect (4). Thus, there is concern that bisphosphonates, in depressing bone turnover, may exacerbate adynamic bone disease in renal transplant recipients (21).

The purpose of this study was to determine whether pamidronate, a bisphosphonate, when given prophylactically, is useful in preserving BMD after renal transplantation and whether it is associated with oversuppression of bone turnover and thus a higher risk of adynamic bone disease.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Study Design
A prospective, randomized, controlled, clinical trial was designed to evaluate the effect of pamidronate on BMD, bone biochemical parameters, and bone histology in adult patients who received a renal transplant. The study was approved by the Institutional Review Board of Montefiore Medical Center. All subjects gave informed consent. They were recruited between August 1, 1999, and November 30, 2000, and followed for 1 yr from entry into the study.

Subjects
Inclusion criteria encompassed all adult transplant recipients who were hemodynamically stable perioperatively. The recipients were approached either before the renal transplant or within 36 h postoperatively if their BP and electrolytes were stable. A negative serum pregnancy test was required before the surgery. Exclusion criteria included inability to return for regular follow-up or participation in another clinical trial.

Protocol
Subjects were randomized via a computer-generated number system to one of two groups. The treatment group (PAM) received intravenous pamidronate plus oral calcitriol and calcium carbonate. The control group (CON) received oral calcitriol and calcium carbonate alone. PAM patients received 60 mg of pamidronate within 48 h after transplantation followed by 30 mg at months 1, 2, 3, and 6. Subjects in both groups received oral calcitriol and calcium carbonate from months 1 to 12 to maintain serum calcium between 8.5 and 10.5 mg/dl. Pamidronate was chosen because it is the only bisphosphonate whose use is not explicitly contraindicated in renal failure, it has a good safety profile in renal failure, and it can be given intravenously.

A subgroup of subjects who were undergoing scheduled living donor renal transplantation underwent anterior iliac crest biopsies immediately before transplantation and 6 mo thereafter. When possible, the subjects received tetracycline for labeling of bone before the baseline bone biopsy (we were unable to complete tetracycline labeling in some cases because of the inability to predict the exact timing of the transplantations); all subjects who underwent follow-up bone biopsy received tetracycline labeling. The labeling schedule consisted of 2-d oral administration of tetracycline hydrochloride (500 mg twice daily), followed by a free interval of 12 d and subsequent administration of 4 d of demeclocycline (300 mg twice daily). Bone biopsies were performed 4 d thereafter. Bone biopsies (0.5 cm diameter x 2 to 4 cm length) were taken from the anterior iliac crest using the one-step electric drill technique (Straumann Medical, Waldenburg, Switzerland; MD Tech) as described previously (22).

Subjects received standard immunosuppression with glucocorticoids and cyclosporine or tacrolimus. During the study, episodes of acute rejection and doses of glucocorticoids, cyclosporine, and tacrolimus were recorded.

Biochemical and Hormonal Determinations
Bone biochemical parameters including intact PTH measured by chemiluminescence method (Immulite), serum osteocalcin (OC), bone-specific alkaline phosphatase (BSAP), and urinary N-telopeptide (UNTx) were obtained at baseline and monthly for the next 12 mo. Blood levels of vitamin D were obtained at baseline and at 6 and 12 mo.

Bone Densitometry and Radiographic Studies
BMD of the vertebral spine (L1 to L4) and hip was measured at baseline and at 6 and 12 mo, using the same Hologic 4500 QDC scanner. Vertebral and hip radiographs were obtained at baseline and at 12 mo and evaluated for radiographic evidence of bone fractures.

Mineralized Histology and Bone Histomorphometry
Iliac bone samples were fixed in absolute ethanol, dehydrated, and embedded in methylmethacrylate as described previously (22). Serial sections of 3- and 7-µm thickness were cut with a Microm microtome, model HM360 (Carl Zeiss, Thornwood, NY). Three-micrometer-thick sections were stained with the modified Goldner Trichrome stain (23). Seven-micrometer-thick, unstained sections were prepared for phase contrast and fluorescence light microscopy and staining for detection of aluminum (24,25).

Histomorphometry of the bone was performed at a standardized site in deep cancellous bone. Static and dynamic parameters of bone structure, formation, and resorption were measured with the Osteoplan system II (Carl Zeiss, Thornwood, NY) (26,27). Histologic features were measured at a magnification of x200. All parameters used are in compliance with and were calculated according to the recommendations of the histomorphometry nomenclature committee of the American Society of Bone and Mineral Research (28). All samples were processed and analyzed in a similar manner and were evaluated in a blinded manner, i.e., without knowledge of treatment assignment.

Statistical Analyses
Power calculations were based on previously reported changes in vertebral BMD in renal transplant recipients (9). The power, set at 80% to detect an 8% difference in vertebral BMD in PAM versus CON at 12 mo, required a total of 60 participants.

Differences between PAM and CON groups were analyzed by t test. Paired t test detected differences in the same subject at two different time points. Independent t test compared the same time point in two different populations. ANOVA detected differences in parameters in more than three groups. In normally distributed results, multivariate linear regression analysis was used to determine which independent variables significantly influenced the dependent variable (change in vertebral BMD and percentage change in vertebral BMD at 6 and 12 mo). Independent variables included in the multivariate analyses were those that were significant on univariate analysis. The statistical program SPSS-8 was used to analyze the data. Means are reported as ± SD.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
A total of 112 adults received a renal transplant during the period and were screened: 26 patients declined to participate, and 14 patients were ineligible. Thus, 72 subjects were enrolled into the protocol and were randomized to 36 PAM and 36 CON.

No significant differences were found between the subjects who were randomized and those who were not randomized in terms of age, gender, race, and cause of ESRD and time on dialysis (Table 1). There were no adverse events related to the pamidronate infusion.


View this table:
[in this window]
[in a new window]

  		Table 1. Transplant recipients: characteristics of subjects versus nonparticipants
 
Dropouts and Demographics
Of the 72 randomized subjects, 13 (five in PAM and eight in CON) did not complete the study. Their data were excluded from analysis as they dropped out early in the study and no treatment data were available. Reasons for not completing the study included primary graft failure, loss to follow-up, refusal to continue participation, and one death from myocardial infarction. Thus, 59 subjects were included in the final cohort for analysis, 31 in PAM and 28 in CON.

There was no significant difference in age, race, BMI, and time on dialysis between the two groups. There were more women in the control group (Table 2).


View this table:
[in this window]
[in a new window]

  		Table 2. Subject demographics
 
Immunosuppression
During the study period, there were no differences between PAM and CON in immunosuppressive therapy; number of rejection episodes (0.27 ± 0.5 versus 0.29 ± 0.5); adverse events (0.87 ± 0.8 versus 1.0 ± 0.6); or cumulative doses of glucocorticoid (6.3 ± 1.1 versus 5.8 ± 1.7 g), cyclosporine (126.3 ± 46 versus 118 ± 31 g), or tacrolimus (4.7 ± 3 versus 5.5 ± 3 g).

Biochemical and Hormonal Parameters
There were no significant differences between PAM and CON in baseline chemistries, vitamin D, PTH, BSAP, OC, and UNTx. Serum creatinine decreased significantly (P < 0.05) and similarly in both groups. Overall, no significant differences were observed between the two groups in serum calcium, phosphorus, bicarbonate, and magnesium. Likewise, no significant differences were found between the two groups in biochemical parameters of bone turnover and hormone levels at 6 and 12 mo (Table 3). There were no differences in baseline and at 6 and 12 mo in biochemical and hormonal parameters in patients who were treated with tacrolimus versus cyclosporine (data not shown).


View this table:
[in this window]
[in a new window]

  		Table 3. Bone biochemical and hormonal parametersa
 
Bone Mineral Density
Fifty-five subjects had baseline bone densitometry. Vertebral and hip BMD were not different between PAM and CON at baseline.

Forty of the 55 subjects had bone densitometry at baseline and 6 mo, 50 subjects had bone densitometry at baseline and 12 mo, and 35 subjects had densitometries at baseline and at 6 and 12 mo. There was no difference in baseline measurements between the group that had two densitometries and the group that had all three studies.

Vertebral BMD
Vertebral BMD was higher at 6 mo in PAM than in CON (1.0345 ± 0.22 versus 0.8803 ± 0.12 g calcium/cm2; P < 0.017). The percentage decrease in vertebral BMD from baseline was significantly less in PAM as compared with CON (-0.63 ± 0.03 versus 4.6 ± 0.08%; P < 0.05; Figure 1).



View larger version (17K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 1. Percentage change in vertebral bone mineral density. *P < 0.05; **P < 0.01.

 
The change (absolute or percentage change) in vertebral BMD at 12 mo was significantly less in PAM (who had not received pamidronate in months 6 to 12) than in CON (0.0105 ± 0.006 versus 0.0599 ± 0.009 g/cm2 [P < 0.033] and -0.39 ± 0.05 versus -5.81 ± 0.09% [P < 0.01]; Figure 1).

Men in PAM showed a lesser decrease in vertebral BMD at 6 mo than men in CON (1.011 ± 0.12 versus 0.8975 ± 0.11 g/cm2; P < 0.036). Women in PAM tended to have preserved BMD as opposed to the women in CON (1.054 ± 0.28 versus 0.8583 ± 0.15 g/cm2; P < 0.064). Neither tacrolimus nor cyclosporine had a further effect on vertebral BMD in either PAM or CON.

Univariate analysis of covariates that were significantly associated with vertebral BMD at 6 mo included pamidronate use, creatinine at 6 mo, vitamin D 25, and BSAP. Those significant with the absolute change and percentage change at 12 mo included pamidronate use and race.

As the bone mineral densities were normally distributed at baseline and at 6 and 12 mo, multivariate linear regression analyses that included variables that were significant on univariate analysis were performed. Pamidronate use was significantly related to vertebral BMD at 6 mo (P < 0.015) as was BSAP (P < 0.029). Pamidronate use and race were significantly related to the percentage change of vertebral BMD at 6 and 12 mo (Table 4).


View this table:
[in this window]
[in a new window]

  		Table 4. Multivariate analysis of predictors of vertebral bone mineral densitya
 
Hip BMD
Hip BMD, as measured by bone densitometry, did not change appreciably at 6 and 12 mo in either PAM (0.9131 ± 0.21 and 0.8933 ± 0.20) or CON (0.8289 ± 0.13 and 0.8216 ± 0.12). There was no significant difference between the two groups at any time during the treatment year (Figure 2). Tacrolimus or cyclosporine did not affect hip BMD.



View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 2. Hip bone mineral density (PNS).

 
Fractures
Vertebral fractures diagnosed by x-ray were present at baseline in four participants. There were three new vertebral fractures at 12 mo (one PAM, two CON). There were no hip fractures during the year of study.

Bone Biopsy
Demographics.
Twenty-six subjects underwent living donor renal transplants; 21 had baseline bone biopsies (eight PAM, 13 CON); 14 had follow-up biopsies at 6 mo of protocol (six PAM, eight CON). The bone biopsy population was similar to the total nonbiopsy population in terms of gender, race, BMI, ESRD distribution, and biochemical parameters. The baseline biopsy subjects had had less time on dialysis (1.7 ± 2.2 versus 4.8 ± 3.9 yr). Similarly, the subjects who had follow-up bone biopsies were not different from the nonbiopsy population except for less time on dialysis (1.8 ± 2 versus 4.3 ± 4 yr, Table 5). They received standard immunosuppression with corticosteroids and cyclosporine or tacrolimus.


View this table:
[in this window]
[in a new window]

  		Table 5. Characteristics of bone biopsy population as compared with nonbiopsy population
 
Histomorphometry.
Histomorphometry was consistent with adynamic bone disease at baseline in 11 of 21 patients on the basis of static parameters of cellularity, woven osteoid, and fibrosis (Table 6). There was no evidence of aluminum bone disease in any of the biopsies. Histomorphometric findings in the follow-up biopsies of the individual patients are shown in Table 7. At 6 mo, there was no loss of cancellous bone volume or trabecular thickness in PAM, whereas CON showed lower cancellous bone volume and decreased trabecular thickness. There was decreased erosion depth in PAM compared with CON. We found that both groups in general showed decreased bone activity in terms of static and dynamic parameters. There was a decrease in cellular elements in both groups. Five of the six subjects developed adynamic bone disease, and one continued to have adynamic bone disease; all six PAM subjects demonstrated a low activation frequency, significantly lower than CON (0.049 ± 0.031 versus 0.381 ± 0.112l; P < 0.022, PAM versus CON), consistent with adynamic bone disease (Table 7). CON developed decreased bone turnover in four of the eight subjects; two of the eight subjects developed higher turnover from baseline adynamic histology, and two continued to have adynamic bone disease (Figure 3).


View this table:
[in this window]
[in a new window]

  		Table 6. Histomorphometric parameters in pamidronate and control groups
 

View this table:
[in this window]
[in a new window]

  		Table 7. Histomorphometry in subjects who had follow-up biopsies
 


View larger version (26K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 3. Bone histomorphometry. Distribution of histomorphometry based on static and dynamic parameters. —, pamidronate; {image}, control.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
This prospective, randomized, clinical trial describes the effects of pamidronate, a bisphosphonate, on bone health of renal transplant recipients. The study, which includes both men and women, confirms that pamidronate ameliorates bone loss as reported by Fan et al. (18) in men alone. Although there was a downward trend noted in the vertebral BMD after the last dose of pamidronate, PAM continued to have significantly higher BMD than did CON.

Hip BMD did not change appreciably in either PAM or CON during the year of study. Both CON and PAM received vitamin D and calcium, which are commonly prescribed in patients who receive long-term steroid therapy for various underlying conditions (3,5,6). Vitamin D and calcium were not given in the previously reported trials of use of bisphosphonates in renal transplant recipients (18,19), possibly accounting for the decrease in hip BMD in their control groups during their study period. In addition, as the hip consists mainly of cortical bone, which has lower remodeling rates than the mainly cancellous bone found in the vertebrae, it may require a longer time of observation before any treatment differences can be detected.

Vertebral BMD results at 6 mo were corroborated by trends observed in changes in iliac crest bone volume and trabecular thickness at follow-up bone biopsies. The bone activity present at baseline was interpreted without the benefit of tetracycline to quantify the bone turnover so that baseline diagnoses were made on static parameters only. Nonetheless, we were able to distinguish among the various classifications of renal osteodystrophy on the basis of the presence and the quality of the cellular and architectural elements. This technique has been useful to classify renal osteodystrophy (22,29,30). The cellular parameters of bone formation and resorption (osteoclasts and osteoblasts number/bone length) revealed an impressive decline after 6 mo of pamidronate treatment. In CON, mean values of these parameters also fell but were less pronounced. These observations are in keeping with known effects of bisphosphonates on bone turnover (31) and the turnover-reducing effects of steroids (3,5). The histologic findings raise the concern of adynamic bone as a possible complication of the positive effects of pamidronate. Further studies are needed to determine whether this may reduce overall bone strength and thus increase the risk of fractures.

Standard biochemical parameters of bone metabolism such as UNTx, BSAP, and OC, although useful in monitoring bone health in the nonrenal transplant patient (32), did not predict bone activity or mineralization in the renal transplant recipient in our study. Because serum phosphorus levels were not different between PAM and CON, the observed findings do not seem to be a result of low phosphate levels.

PTH may affect vertebral BMD. In the nonrenal patient, PTH may have an anabolic effect on vertebral BMD and may increase measured density. Exogenous PTH may be useful in improving bone health in osteoporotic patients (33,34). In our study, PTH was similarly corrected in both PAM and CON, thus rendering an added influence of PTH on BMD unlikely.

The total amounts of immunosuppressive agents were similar in both groups, thus eliminating a specific effect of these drugs on BMD. Likewise, the total dose of corticosteroids was similar in both groups.

This study suggests that pamidronate can preserve vertebral BMD in renal transplant recipients when it is given prophylactically, at the time of renal transplantation. BMD continued to be maintained even after pamidronate was stopped, as compared with CON receiving vitamin D and calcium alone. It is likely to have a similar effect on hip BMD.

Loss of BMD is associated with increased fracture risk (35,36). Although the number of fractures at 12 mo was too small in our study to analyze, it would be expected that the better preserved vertebral BMD at 1 yr in PAM would be associated with decreased fracture risk. A recent study using the bisphosphonate ibandronate prophylactically in renal transplant recipients did not decrease the rate of vertebral fractures, although BMD increased (37). Of concern is the tendency toward very low bone turnover evidenced by bone histology at 6 mo in our study. We and others have reported that low PTH and presumably low bone turnover are associated with increased fractures in dialysis patients (38,39). Whether low bone turnover with increased bone density in these subjects treated with bisphosphonates carries the same risks associated with adynamic bone disease in dialysis patients is unclear (21).

That pamidronate is effective in preserving BMD is shown by the present study. Although the bone histology seems to have been affected by pamidronate, our study was not powered to detect differences on the effect that the bisphosphonate might have on bone turnover. Before our study, no data existed to demonstrate such an effect, so it was not possible to power the study to show a difference. In addition, because we did not have quantifiable measures of bone turnover because of lack of tetracycline double labeling on the baseline bone biopsies, we are not able to report a measured difference in bone turnover at the follow-up biopsy. Therefore, conclusions regarding the effect of bisphosphonates on renal transplant osteodystrophy cannot be reached on the basis of the histologic observations seen in our study but may serve as a basis of future investigation.

In summary, the present study demonstrates that bisphosphonate therapy in the adult with a new renal transplant is associated with preserved BMD and low bone turnover. Whether this therapy is useful in attenuating long-term bone loss of renal transplantation and decreasing bone fractures in this population of renal patients will require further study.


   Acknowledgments
 
This study was presented, in part, at the American Society of Nephrology National Meeting, Philadelphia, PA, 2003.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Malluche H, Faugere MC: Renal bone disease in 1990: An unmet challenge for the nephrologists. Kidney Int 38: 193–211, 1990[Medline]
  2. Sherrard D, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure: An evolving disorder. Kidney Int 43: 436–442, 1993[Medline]
  3. Ziegler R, Kasperk C: Glucocorticoid-induced osteoporosis: Prevention and treatment. Steroids 63: 344–348, 1998[CrossRef][Medline]
  4. Faugere MC, Mawad H, Qi Q, Friedler R, Malluche H: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11: 1093–1099, 2000[Abstract/Free Full Text]
  5. Lane N, Lukert B: The science and therapy of glucocorticoids-induced bone loss. Endocrinol Metab Clin North Am 27: 465–483, 1998[CrossRef][Medline]
  6. Eastell R, Reid DM, Compston J, Cooper C, Fogelman R, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell R, Stevenson JC, Torgerson DJ: A UK Consensus Group on management of glucocorticoids induces osteoporosis: An update. J Intern Med 224: 271–292, 1998
  7. Movsowitz C, Schlosberg M, Epstein S, Ismail F, Fallon M, Thomas S: Combined treatment with cyclosporine A and cortisone acetate minimizes the adverse bone effects of either agent alone. J Orthop Res 635: 641, 1990
  8. Wolpaw T, Deal C, Fleming-Brooks S, Bartucci M, Schulak J, Hricik D: Factors influencing vertebral bone density after renal transplantation. Transplantation 58: 1186–1189, 1994[Medline]
  9. Julian B, Laskow D, Dubovsky J, Dubovsky EV, Curtis J, Quarles LD: Rapid loss of vertebral bone mineral density after renal transplantation. N Engl J Med 325: 544–550, 1991[Abstract]
  10. Chiu M, Sprague S, Bruce D, Woodle E, Thistlewaite J, Josephson M: Analysis of fracture prevalence in kidney pancreas allograft recipients. J Am Soc Nephrol 677: 683, 1998
  11. Adachi JD, Benson W, Brown J, Hanley D, Hodsman A, Josse R, Kendler D, Lentle B, Olszynski W, Ste-Marie L, Tenenhouse A, Chines A: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337: 382–387, 1997[Abstract/Free Full Text]
  12. Saag KG, Emkey R, Schnitzer T, Brown J, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG: Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. N Engl J Med 339: 292–299, 1998[Abstract/Free Full Text]
  13. Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufilanchas J, Hawkins F: Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 60: 155–159, 1997[CrossRef][Medline]
  14. Bianda T, Linka A, Junga G, Brunner H, Steinhart H, Kiowski W, Schmid C: Prevention of osteoporosis in heart transplant recipients: A comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 67: 116–121, 2000[CrossRef][Medline]
  15. Bishop NJ, Ninkovic M, Alexander G, Holmes S, Milligan T, Price C, Compston J: Changes in calcium homoeostasis in patients undergoing liver transplantation: Effects of a single infusion of pamidronate administered pre-operatively. Clin Sci 97: 157–163, 1999[Medline]
  16. Riemens SC, Oostdijk A, van Doormaal J, Thijn C, Drent G, Piers D, Goen E, Meerman L, Sloof M, Haagsma E: Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. Osteoporos Int 6: 213–218, 1996[Medline]
  17. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F: Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 57: 15–19, 1995[CrossRef][Medline]
  18. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, Olschewski M, Schollmeyer PJ: Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 66: 1004–1008, 1998[Medline]
  19. Fan S, Almond M, Ball E, Evans K, Cunningham J: Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57: 684–690, 2000[Medline]
  20. Briner V, Thiel G, Monier-Faugere MC, Bognar B, Landmann J, Kamber V, Malluche H: Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 Vitamin D levels two years after kidney transplantation. Transplantation 59: 1393–1400, 1995[Medline]
  21. Weber T, Quarles LD: Preventing bone loss after renal transplantation with bisphosphonates: We can ... but should we? Kidney Int 57: 735–737, 2000[CrossRef][Medline]
  22. Malluche HH, Faugere MC: Atlas of Mineralized Bone Histology, New York, Karger, 1986
  23. Goldner J: A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14: 237, 1938
  24. Lillie RD, Donaldson P, Jirge SK, Pizzolato P: Iron and aluminum lakes of Gallo blue E as nuclear and metachromatic stains. Stain Technol 51: 187–192, 1976[Medline]
  25. Denton J, Freemont AJ, Ball J: Detection and distribution of aluminium in bone. J Clin Pathol 37: 136–42, 1984[Abstract/Free Full Text]
  26. Malluche HH, Sherman D, Meyer W, Massry SG: A new semiautomatic method for quantitative static and bone histology. Calcif Tissue Int 34: 439–438, 1982[CrossRef][Medline]
  27. Manaka RC, Malluche HH: A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. Comput Programs Biomed 12: 191–210, 1981
  28. Parfitt AM, Dresner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595–610, 1987[Medline]
  29. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, Oberbauer R: Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63: 1130–1136, 2003[CrossRef][Medline]
  30. Rojas E, Carlini R, Clesca P, Arminio A, Suniaga O, Elguezabal K, Weisinger J, Hruska K, Bellorin-Front E: The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 63: 1915–1923, 2003[CrossRef][Medline]
  31. Fleisch H: Bisphosphonates: Mechanisms of action. Endocr Rev 19: 80, 1998[Abstract/Free Full Text]
  32. Christenson R: Biochemical markers of bone metabolism: An overview. Clin Biochem 30: 573–593, 1997[CrossRef][Medline]
  33. Finkelstein JS, Klibanski A, Schaefer EH, Hornsten MD, Schiff I, Neer RM: Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331: 1618–1623, 1994[Abstract/Free Full Text]
  34. Neer R, Arnaud C, Zanchetti J, Prince R, Gaich G, Reginster J, Hodsman A, Eriksen E, Sharlom S, Genant H, Wang O, Mitlak B, Mellstrom D, Oefiord E, Suchowierska E, Salmi J, Mulder H, Halse J, Sawick A: Effect of parathyroid hormone (1-34) on fractures and BMD in post-menopausal women with osteoporosis. N Engl J Med 344: 1434–1441, 2001[Abstract/Free Full Text]
  35. Lips P: Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 103: 3S–8S, 1997[Medline]
  36. Ross PD: Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am 27: 289–301, 1998[CrossRef][Medline]
  37. Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen K, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump L: Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12: 1530–1537, 2001[Abstract/Free Full Text]
  38. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33: 287–293, 1999[Medline]
  39. Coco M, Rush H: Increased incidence of hip in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 1115–1121, 2000[Medline]
Received for publication March 31, 2003. Accepted for publication July 5, 2003.




This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
A. Qaseem, V. Snow, P. Shekelle, R. Hopkins Jr., M. A. Forciea, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee
Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians
Ann Intern Med, September 16, 2008; 149(6): 404 - 415.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
C. MacLean, S. Newberry, M. Maglione, M. McMahon, V. Ranganath, M. Suttorp, W. Mojica, M. Timmer, A. Alexander, M. McNamara, et al.
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
Ann Intern Med, February 5, 2008; 148(3): 197 - 213.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
U. Kunzendorf, B. K. Kramer, W. Arns, J. Braun, J. Grossmann, F. Pietruck, H. Schmidt-Gayk, A. Schwarz, E. Ziegler, H. Sperschneider, et al.
Bone disease after renal transplantation
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 450 - 458.
[Full Text] [PDF]

Home page
 NDT PlusHome page
M. Chonchol and R. P. Wuthrich
Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease
NDT Plus, January 1, 2008; 1(suppl_1): i36 - i41.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Cunningham
Bisphosphonates in the renal patient
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1505 - 1507.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. Cunningham
Pathogenesis and Prevention of Bone Loss in Patients Who Have Kidney Disease and Receive Long-Term Immunosuppression
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 223 - 234.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
J. R. Weisinger, R. G. Carlini, E. Rojas, and E. Bellorin-Font
Bone Disease after Renal Transplantation
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1300 - 1313.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Mitterbauer, C. Schwarz, M. Haas, and R. Oberbauer
Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials
Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2275 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Westenfeld, M. Ketteler, and V. M. Brandenburg
Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density
Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2075 - 2077.
[Full Text] [PDF]

Home page
 CJASNHome page
A. Djamali, M. Samaniego, B. Muth, R. Muehrer, R. M. Hofmann, J. Pirsch, A. Howard, G. Mourad, and B. N. Becker
Medical Care of Kidney Transplant Recipients after the First Posttransplant Year
Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 623 - 640.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. Ketteler, G. Schlieper, and J. Floege
Calcification and Cardiovascular Health: New Insights Into an Old Phenomenon
Hypertension, June 1, 2006; 47(6): 1027 - 1034.
[Full Text] [PDF]

Home page
 CJASNHome page
K. Olgaard and E. Lewin
Can Hyperparathyroid Bone Disease Be Arrested or Reversed?
Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 367 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Nutr Clin PractHome page
H. Ohlrich, K. Barco, and M. R. Silver
The Use of Parenteral Nutrition in a Severely Malnourished Hemodialysis Patient With Hypercalcemia
Nutr Clin Pract, October 1, 2005; 20(5): 559 - 568.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Kananen, L. Volin, K. Laitinen, H. Alfthan, T. Ruutu, and M. J. Valimaki
Prevention of Bone Loss after Allogeneic Stem Cell Transplantation by Calcium, Vitamin D, and Sex Hormone Replacement with or without Pamidronate
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3877 - 3885.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. M. Maalouf and E. Shane
Osteoporosis after Solid Organ Transplantation
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2456 - 2465.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Lee, D. Glicklich, and M. Coco
Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction
Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2870 - 2873.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coco, M.
Right arrow Articles by Malluche, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coco, M.
Right arrow Articles by Malluche, H.

HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP